According to Jefferies, VIVUS VVUS has determined that it is feasible to conduct a retrospective safety analysis (FORTRESS) of commercial topiramate use to rule out risk of birth defects with Qnexa.
Jefferies said that VVUS reiterated its refiling guidance of 4Q11. “Although VVUS discussed a new backup strategy to limit Qnexa to men and non-child-bearing women if
FORTRESS results are unfavorable, we remain concerned with approvability. Our $3 PT is based on 20X 2016E EPS, discounted 35%. The 20x multiple is in line with small/ mid-cap biotechs. Risks: regulatory approval, patent protection and commercial uptake.”
VIVUS closed yesterday at $7.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in